Compare Alexandria Real Estate Equities Inc (ARE) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alexandria Real Estate Equities Inc vs BioNano Genomics Inc — how do they compare? Alexandria Real Estate Equities Inc trades at $48.08 (market cap $8.28B), while BioNano Genomics Inc trades at $1.19 (market cap $13.66M). The key difference: Alexandria Real Estate Equities Inc is far larger — about 606.1× BioNano Genomics Inc's market cap, and Alexandria Real Estate Equities Inc pays a 5.99% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| ARE | BNGO | |
|---|---|---|
Market Cap | $8.28B | $13.66M |
Sector | Real Estate | Health |
52-Week High | $87.45 | $4.92 |
52-Week Low | $40.41 | $1.06 |
Enterprise Value | $20.98B | $16.26M |
Dividend Yield | 5.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alexandria Real Estate Equities (ARE) trades at $48.35, down 2.79% today, with a bearish technical signal and mixed fundamentals. The stock shows a negative net income margin of -37.12% for 2025, though recent Q2 2026 FFO beat estimates. Analyst consensus is a 'Buy' with a $53.71 price target, but technical indicators suggest near-term pressure with support at $47 and resistance at $50.
Outlook remains cautious due to profitability challenges and high debt, but leasing momentum and strategic partnerships offer recovery potential. Risks include ongoing net losses and market volatility, while institutional interest and dividend payments provide some stability. Investors should weigh fundamental weaknesses against long-term real estate sector recovery prospects.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
